Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Targeted Renal Therapy Clear all
Not yet recruiting Phase 2 Interventional

Precision T1D Platform - New Therapies for Cardio-Renal Complications

NCT07594145
View directory record Official record
Conditions
Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
Interventions
Finerenone, Sotagliflozin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Ann Arbor, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 3, 2026, 9:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

NCT01136733
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Lenvatinib, Everolimus
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 3, 2026, 9:34 PM EDT
Completed No phase listed Observational

Cardiovascular Effects of Sunitinib Therapy (CREST)

NCT01370109
View directory record Official record
Conditions
Renal Cell Carcinoma 4
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 3, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Zoledronate With Atorvastatin in Renal Cell Carcinoma

NCT00490698
View directory record Official record
Conditions
Kidney Cancer, Renal Cell Carcinoma
Interventions
Zoledronate, Atorvastatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2013 · Synced Sep 3, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

NCT00790400
View directory record Official record
Conditions
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Interventions
Everolimus (RAD001), Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Sep 3, 2026, 9:34 PM EDT
Recruiting Phase 1 Interventional

A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma

NCT07688187
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
PD-32766D (a Copper-64 [64Cu] labeled peptide), PD-32766T (an Actinium-225 [225Ac] labeled peptide)
Drug
Lead sponsor
PeptiDream Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 3, 2026, 9:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

NCT01326871
View directory record Official record
Conditions
Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis
Interventions
Cisplatin, Gemcitabine, ALT-801
Drug · Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
16
States / cities
Tucson, Arizona • Orlando, Florida • Stuart, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 3, 2026, 9:34 PM EDT
Terminated Phase 2 Interventional Results available

Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

NCT02560012
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Sunitinib, Temsirolimus, Sorafenib, Pazopanib, Everolimus, Axitinib
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 3, 2026, 9:34 PM EDT
Active, not recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
Interventions
Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1405
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 3, 2026, 9:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

NCT06897930
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
AZD0120, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 3, 2026, 9:34 PM EDT
Completed Phase 1Phase 2 Interventional

Belimumab Impacting Transplant Eligibility

NCT02500251
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
belimumab, Bortezomib, Rituximab, Plasmapheresis
Drug
Lead sponsor
E. Steve Woodle
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Sep 3, 2026, 9:34 PM EDT
Recruiting Phase 4 Interventional

Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

NCT07169825
View directory record Official record
Conditions
Lu-177 PSMA
Interventions
Lu-177, SPECT
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 3, 2026, 9:34 PM EDT
Completed Phase 1 Interventional

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

NCT02223052
View directory record Official record
Conditions
Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
Interventions
CC-486, Vidaza
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 3, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Alternating Sunitinib and Temsirolimus

NCT01517243
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Sunitinib, Temsirolimus
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Lebanon, New Hampshire • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 3, 2026, 9:34 PM EDT
Recruiting Phase 1 Interventional

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

NCT07115745
View directory record Official record
Conditions
Refractory Autoimmune Diseases
Interventions
BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab
Genetic · Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 3, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Randomized Trial for Mixed Acute Rejection

NCT00771875
View directory record Official record
Conditions
Graft Rejection
Interventions
Rabbit Antithymocyte Globulin (RATG), Rituximab, Bortezomib, Acetaminophen, Antihistamine, Methylprednisolone
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 3, 2026, 9:34 PM EDT
Recruiting Phase 1 Interventional

Treatment of Antibody-Mediated Rejection (ABMR) With CarBel

NCT06918990
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Carfilzomib, Belatacept
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 3, 2026, 9:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

NCT02111850
View directory record Official record
Conditions
Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma, Breast Cancer
Interventions
Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL), Cyclophosphamide, Fludarabine, Aldesleukin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 3, 2026, 9:34 PM EDT
Recruiting Phase 1 Interventional

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

NCT06479811
View directory record Official record
Conditions
Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma, Olfactory Neuroblastoma, Somatostatin Receptor Positive, Small Cell Lung Cancers, Pheochromocytoma/Paragangliomas, Kidney Cancers, Head and Neck Tumors, Gastrointestinal Neuroendocrine Tumors
Interventions
68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 3, 2026, 9:34 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

NCT06255028
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
Interventions
CNTY-101, IL-2, Lymphodepleting Chemotherapy
Biological · Drug
Lead sponsor
Century Therapeutics, Inc.
Industry
Eligibility
17 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Sacramento, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 3, 2026, 9:34 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

NCT07015983
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions
CC-97540, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
16 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
41
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 3, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

NCT00378703
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate, Temsirolimus
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
558
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 356 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 3, 2026, 9:34 PM EDT
Terminated Phase 2 Interventional

Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

NCT00440973
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Bevacizumab, Interleukin-2
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 3, 2026, 9:34 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

NCT06390826
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging, Sunitinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 3, 2026, 9:34 PM EDT